Pulse Biosciences Reports First Quarter 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/29/2026
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- HF Sinclair plans to spin off lubricants unit, close Canadian refinery
- SoFi Technologies (SOFI) Tops Q2 EPS by 1c ; Offers Guidance
- S&P 500 ends higher as investors await tech earnings
- Crude Inventory Fell 7.2 Million Barrels Last Week - EIA
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
- After-Hours Stock Movers: GOOGL, TSLA, NOW, IBM, TXN, MOH, URI
- After-Hours Stock Movers: SMCI, OKLO, XE, PEGA, CLDX, ALK
Pulse Biosciences, Inc. (PLSE) Misses Q1 EPS by 10c
May 11, 2020 4:52 PM EDTPulse Biosciences, Inc. (NASDAQ: PLSE) reported Q1 EPS of ($0.57), $0.10 worse than the analyst estimate of ($0.47).
Recent Highlights
Completed Pre-Submission meeting with the U.S. Food and Drug Administration (FDA) to establish the criteria for the studies required for a 510(k) submission for the CellFX System for a general indication in aesthetic dermatologyObtained ISO-13485:2016 Quality System Management Certification to begin preparations for... More